UBS lowered the firm’s price target on Surgery Partners (SGRY) to $21 from $29 and keeps a Buy rating on the shares. The company attributed the Q4 EBITDA miss to underperformance at three specific surgical hospital markets, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners price target lowered to $24 from $30 at Benchmark
- Surgery Partners price target lowered to $20 from $31 at RBC Capital
- Surgery Partners Earnings Call Balances Growth And Strain
- Surgery Partners price target lowered to $17.50 from $24 at BofA
- Morning Movers: Pinterest jumps following $1B investment from Elliot